31/03/2026
Hi everyone,
Some promising news to share with the community!
💗 Ultragenyx Pharmaceutical has received FDA clearance to begin a clinical trial for a potential new treatment for GNE myopathy (called UX016). 💚
What this means in simple terms:
• The treatment can now move into human trials (Phase 1/2)
• The study is expected to start later in 2026
• It will look at safety first, but also whether it can help muscle function
This treatment is designed to help the body better deliver sialic acid to muscles, which is something people with GNE myopathy struggle to produce.
It’s still early days, and there’s no guarantee yet, but this is an important step forward, especially as there are currently no approved treatments.
Also worth noting: this work is being supported through a patient-led funding approach, which shows the power of our community in driving research forward 💪🏽
As always, I’ll share updates as things progress.
What are your thoughts on this?